Covered recipient · General Payments record
ALMA CRUZ SANTANA
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$3,010.96
57 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,846.01 | 55 |
| Consulting Fee | $1,100.00 | 1 |
| Education | $64.95 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $1,648.75 | 16 |
| Novartis Pharmaceuticals Corporation | $694.02 | 17 |
| UCB, Inc. | $118.75 | 3 |
| Organon Llc | $117.71 | 5 |
| Eli Lilly Export S.A. Puerto Rico Branch | $116.97 | 5 |
| Janssen Biotech, Inc. | $64.95 | 1 |
| GENZYME CORPORATION | $63.23 | 2 |
| PBG PUERTO RICO LLC | $44.32 | 2 |
| Eli Lilly and Company | $41.68 | 1 |
| E.R. Squibb & Sons, L.L.C. | $40.78 | 2 |
| Amgen Inc. | $40.00 | 2 |
| Galderma Laboratories, L.P. | $19.80 | 1 |
Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALMA CRUZ SANTANA
NPI 1447364716 · CMS profile ID 945487
Allopathic & Osteopathic Physicians / Dermatology
CAROLINA, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ALMA CRUZ SANTANA, NPI 1447364716, CMS profile ID 945487, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–57 of 57 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447364716?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
57 matching records · $3,010.96 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–57 of 57.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $41.68 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136027372 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $22.50 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136027368 | CMS |
| Novartis Pharmaceuticals Corporation | $21.39 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086617391 | CMS |
| Organon Llc | $25.00 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136230908 | CMS |
| ABBVIE INC. | $19.97 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103519194 | CMS |
| Novartis Pharmaceuticals Corporation | $22.47 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086617389 | CMS |
| PBG PUERTO RICO LLC | $19.32 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130949102 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $46,936.00 | 9 |
| PY2025 | Principal investigator | $256,279.02 | 99 |
| PY2024 | Recipient | $189,454.69 | 35 |
| PY2024 | Principal investigator | $238,009.40 | 77 |
| PY2023 | Recipient | $86,774.62 | 28 |
| PY2023 | Principal investigator | $91,569.79 | 12 |
| PY2022 | Recipient | $83,849.16 | 29 |
| PY2022 | Principal investigator | $73,241.46 | 7 |
| PY2021 | Recipient | $342,872.92 | 31 |
| PY2021 | Principal investigator | $42,578.90 | 16 |
| PY2020 | Recipient | $402,394.09 | 33 |
| PY2020 | Principal investigator | $19,704.41 | 5 |
| PY2019 | Recipient | $747,138.22 | 31 |
| PY2019 | Principal investigator | $322.09 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
108 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $548.00 | 12/31/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202535197 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/31/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202535199 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 12/11/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202530030 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 12/11/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202530062 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 12/11/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202530064 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 12/10/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202529832 |
| Principal investigator 1 | ABBVIE INC. | $251.00 | 12/10/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202529834 |
| Principal investigator 1 | ABBVIE INC. | $5,377.61 | 12/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202527140 |
| Principal investigator 1 | ABBVIE INC. | $9,578.10 | 12/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527142 |
| Principal investigator 1 | ABBVIE INC. | $1,238.30 | 12/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202527344 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 11/25/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202525252 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 11/14/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202524349 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,174.01 | 11/10/2025 | Non-covered Recipient Entity ALMA CRUZ - SANTANA PRIVATE PRACTICE | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190312117 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 11/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523227 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 11/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523251 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 11/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202523253 |
| Principal investigator 1 | ABBVIE INC. | $8,915.30 | 11/05/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521577 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 11/05/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521579 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 11/05/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202521759 |
| Principal investigator 1 | ABBVIE INC. | $23,532.41 | 11/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520297 |
| Principal investigator 1 | ABBVIE INC. | $6,187.60 | 10/09/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515697 |
| Principal investigator 1 | ABBVIE INC. | $1,919.50 | 10/09/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515699 |
| Principal investigator 1 | ABBVIE INC. | $260.00 | 09/17/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202511230 |
| Principal investigator 1 | ABBVIE INC. | $9,690.00 | 09/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509750 |
| Principal investigator 1 | ABBVIE INC. | $1,588.00 | 09/04/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509754 |
| Principal investigator 1 | ABBVIE INC. | $1,914.30 | 09/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202508138 |
| Principal investigator 1 | ABBVIE INC. | $1,422.70 | 09/03/2025 | Non-covered Recipient Entity GRUPO DERMATOLOGICO CAROLINA | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202508140 |
| Principal investigator 1 | ABBVIE INC. | $1,177.20 | 09/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202508142 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 08/26/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505843 |
| Principal investigator 1 | ABBVIE INC. | $251.00 | 08/26/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505857 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 08/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505477 |
| Principal investigator 1 | ABBVIE INC. | $94.90 | 08/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202505479 |
| Principal investigator 1 | ABBVIE INC. | $585.00 | 08/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505507 |
| Principal investigator 1 | ABBVIE INC. | $390.00 | 08/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505509 |
| Principal investigator 1 | ABBVIE INC. | $1,322.80 | 08/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202503205 |
| Principal investigator 1 | ABBVIE INC. | $1,562.00 | 08/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202503207 |
| Principal investigator 1 | ABBVIE INC. | $25,077.30 | 08/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503287 |
| Principal investigator 1 | ABBVIE INC. | $5,196.90 | 07/02/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202496143 |
| Principal investigator 1 | ABBVIE INC. | $4,161.41 | 07/02/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202496151 |
| Principal investigator 1 | ABBVIE INC. | $273.70 | 07/02/2025 | Non-covered Recipient Entity GRUPO DERMATOLOGICO CAROLINA | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202496163 |
| Principal investigator 1 | ABBVIE INC. | $8,614.70 | 07/02/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496335 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 06/18/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202492319 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 06/18/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202492321 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 06/17/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202491895 |
| Principal investigator 1 | ABBVIE INC. | $1,588.00 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487457 |
| Principal investigator 1 | ABBVIE INC. | $1,637.40 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202489539 |
| Principal investigator 1 | ABBVIE INC. | $802.80 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202489775 |
| Principal investigator 1 | ABBVIE INC. | $604.60 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489777 |
| Principal investigator 1 | ABBVIE INC. | $2,990.10 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202489779 |
| Principal investigator 1 | ABBVIE INC. | $3,655.06 | 06/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202489781 |
| Principal investigator 1 | ABBVIE INC. | $520.00 | 05/29/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202486879 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 05/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202485623 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 05/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202485625 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 05/20/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202485473 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 05/20/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202485477 |
| Principal investigator 1 | ABBVIE INC. | $1,322.80 | 05/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482835 |
| Principal investigator 1 | ABBVIE INC. | $2,357.40 | 05/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202482901 |
| Principal investigator 1 | ABBVIE INC. | $15,317.80 | 05/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482903 |
| Principal investigator 1 | ABBVIE INC. | $1,491.00 | 05/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202481481 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 05/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202481483 |
| Principal investigator 1 | ABBVIE INC. | $1,491.00 | 05/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202481539 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 04/24/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202478984 |
| Principal investigator 1 | ABBVIE INC. | $390.00 | 04/24/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202478988 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 04/24/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202479012 |
| Principal investigator 1 | ABBVIE INC. | $1,395.40 | 04/03/2025 | Non-covered Recipient Entity GRUPO DERMATOLOGICO CAROLINA | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202469966 |
| Principal investigator 1 | ABBVIE INC. | $6,846.00 | 04/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470435 |
| Principal investigator 1 | ABBVIE INC. | $1,796.65 | 04/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202470439 |
| Principal investigator 1 | ABBVIE INC. | $1,430.00 | 04/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202470443 |
| Principal investigator 1 | ABBVIE INC. | $2,476.60 | 04/03/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202470602 |
| Principal investigator 1 | ABBVIE INC. | $1,588.00 | 03/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459180 |
| Principal investigator 1 | ABBVIE INC. | $1,430.00 | 03/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202459385 |
| Principal investigator 1 | ABBVIE INC. | $3,906.70 | 03/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202459389 |
| Principal investigator 1 | ABBVIE INC. | $10,275.50 | 03/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202459437 |
| Principal investigator 1 | ABBVIE INC. | $7,001.64 | 03/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202460449 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 03/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202456575 |
| Principal investigator 1 | ABBVIE INC. | $273.70 | 03/06/2025 | Non-covered Recipient Entity GRUPO DERMATOLOGICO CAROLINA | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202456580 |
| Recipient | ABBVIE INC. | $500.00 | 02/27/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202397885 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,000.45 | 02/15/2025 | Non-covered Recipient Entity ALMA CRUZ - SANTANA PRIVATE PRACTICE | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190312119 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 02/13/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202450904 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 02/13/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202450929 |
| Recipient | E.R. Squibb & Sons, L.L.C. | $22,551.00 | 02/13/2025 | Covered Recipient Physician | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1236002305 |
| Recipient | ABBVIE INC. | $6,599.00 | 02/11/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202397880 |
| Principal investigator 1 | ABBVIE INC. | $2,037.48 | 02/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202446764 |
| Principal investigator 1 | ABBVIE INC. | $7,531.60 | 02/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202446850 |
| Principal investigator 1 | ABBVIE INC. | $6,999.20 | 02/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202447297 |
| Principal investigator 1 | ABBVIE INC. | $15,511.30 | 02/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447300 |
| Recipient | ABBVIE INC. | $967.20 | 01/22/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202397872 |
| Recipient | ABBVIE INC. | $483.60 | 01/22/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202397876 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 01/21/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202440356 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 01/16/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202439038 |
| Principal investigator 1 | ABBVIE INC. | $321.68 | 01/16/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202439042 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 01/16/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202439057 |
| Recipient | Novartis Pharmaceuticals Corporation | $500.00 | 01/16/2025 | Covered Recipient Physician | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190291142 |
| Recipient | Novartis Pharmaceuticals Corporation | $6,695.00 | 01/16/2025 | Covered Recipient Physician | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190292731 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 01/15/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202438645 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $112.90 | 01/15/2025 | Non-covered Recipient Entity ALMA CRUZ - SANTANA PRIVATE PRACTICE CAIN457A2326 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190307365 |
| Principal investigator 1 | ABBVIE INC. | $596.70 | 01/14/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202438213 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,786.50 | 01/14/2025 | Covered Recipient Physician | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190292727 |
| Recipient | ABBVIE INC. | $4,853.70 | 01/09/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202397869 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 01/08/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA MD | M16-049 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202437155 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 01/08/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA MD | M16-049 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202437159 |
| Principal investigator 1 | ABBVIE INC. | $548.00 | 01/08/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202437205 |
| Principal investigator 1 | ABBVIE INC. | $195.00 | 01/07/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202436889 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 01/06/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202436753 |
| Principal investigator 1 | ABBVIE INC. | $1,696.40 | 01/02/2025 | Non-covered Recipient Entity GRUPO DERMATOLOGICO CAROLINA | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202433501 |
| Principal investigator 1 | ABBVIE INC. | $1,810.90 | 01/02/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433505 |
| Principal investigator 1 | ABBVIE INC. | $3,114.80 | 01/02/2025 | Non-covered Recipient Entity ALMA M CRUZ-SANTANA | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202433509 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,620.72 | 01/01/2025 | Non-covered Recipient Entity ALMA CRUZ - SANTANA PRIVATE PRACTICE CAIN457A2326 | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190307367 |